WSD0922
Modify Date: 2024-01-03 19:23:36
WSD0922 structure
|
Common Name | WSD0922 | ||
|---|---|---|---|---|
| CAS Number | 2226552-64-1 | Molecular Weight | 442.43 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H21F3N4O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of WSD0922WSD-0922 is a potent, selective, orally active, and BBB penetrable EGFR/EGFRVIII inhibitor. WSD-0922 is against EGFRm+ (EGFRvIII/Del19/L858R) with an IC50 of <10 nM. WSD0922 shows good safety profile and preclinical anti-tumor efficacy[1]. |
| Name | WSD0922 |
|---|
| Description | WSD-0922 is a potent, selective, orally active, and BBB penetrable EGFR/EGFRVIII inhibitor. WSD-0922 is against EGFRm+ (EGFRvIII/Del19/L858R) with an IC50 of <10 nM. WSD0922 shows good safety profile and preclinical anti-tumor efficacy[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: EGFRm+ (EGFRvIII/Del19/L858R)[1] |
| In Vivo | WSD0922 treatment results in tumor regression on cetuximab resistant PDX model of HNSCC. WSD0922 demonstrates remarkable tumor regression in 3 PDX models (platinum sensitive/insensitive/EGFRm+). WSD0922 is well tolerated in GLP tox at dose ~10x clinical equivalent dose.[1] |
| References |
| Molecular Formula | C23H21F3N4O2 |
|---|---|
| Molecular Weight | 442.43 |